TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02285374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
Description: Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
Description: Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
Study: NCT03203850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox FCT
Description: Taken orally once per day (QD) as a film coated tablet (FCT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: according to investigator's decision
Study: NCT03014323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule twice a day for 4 weeks
Study: NCT03550703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-Myoma
Description: Once daily oral pill of V3-Myoma
Study: NCT03239587

Intervention type: BEHAVIORAL
Intervention: Musical Intervention
Description: Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.

Intervention type: PROCEDURE
Intervention: Blood Draws
Description: No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.

Intervention type: PROCEDURE
Intervention: Blood Draws
Description: No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
Study: NCT00941044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Description: application of non-invasive NAVA in healthy volunteers
Study: NCT02287064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immune Globulin (IVIG)
Description: IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion
Study: NCT04287777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin gel
Description: Topical administration of Mupirocin gel 20 mg/g BID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of Placebo (ointment) TID during 7 days
Study: NCT00229255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high frequency of meals
Description: high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: twice a day meals
Description: high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
Study: NCT00990496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Specific Cytotoxic T Lymphocytes (CTL)
Description: CTL Infusion (3 - 5 x 10E6 cells/kg)
Study: NCT03691896

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 400
Description: dose 400 UNT/day for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 800
Description: dose 800 UNT/day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1200
Description: dose 1200 UNT/day for 12 months
Study: NCT02526940

Intervention type: PROCEDURE
Intervention: rectal biopsies
Description: 6 rectal biopsies

Intervention type: PROCEDURE
Intervention: rectal biopsies
Description: 6 rectal biopsies

Intervention type: PROCEDURE
Intervention: rectal biopsies
Description: 6 rectal biopsies

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study: NCT03904758

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pepsin in saliva test
Description: The presence of pepsin in the saliva will be tested in both groups of patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pepsin in saliva test
Description: The presence of pepsin in the saliva will be tested in both groups of patients.
Study: NCT03209427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 100 μg
Description: Intrathecal injection of morphine100 μg
Study: NCT02935023

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CIRT with systemic therapy arm
Description: carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
Study: NCT00420823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taurine 4g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine 4g
Study: NCT03410641

Intervention type: BEHAVIORAL
Intervention: Diet and antismoking advice
Description: Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
Study: NCT01146158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection for breast carcinomas
Description: surgery Axillary dissection
Study: NCT01169233

Intervention type: DEVICE
Group type: OTHER
Intervention: Bright Light Box
Description: Increased lighting used during night shifts to prevent sleepiness.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bright Light Box
Description: Increased lighting used during night shifts to prevent sleepiness.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bright Light Box
Description: Increased lighting used during night shifts to prevent sleepiness.
Study: NCT04524507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-titer Convalescent COVID-19 Plasma (CCP1)
Description: At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-titer Convalescent COVID-19 plasma (CCP2)
Description: At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
Study: NCT00852358

Intervention type: DRUG
Group type: OTHER
Intervention: laronidase
Description: For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laronidase
Description: For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
Study: NCT01586013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evaluation of propofol effect using BIS
Description: propofol administered in target controlled infusion using the pharmacokinetic model of White
Study: NCT03832712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Unselective β-blockers such as Propanolol
Study: NCT03769753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRE Device
Description: For use in ablating soft tissue
Study: NCT02643316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Same day 4 L preparation (Polyethylene Glycol)
Description: Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose 4 L preparation (Polyethylene Glycol)
Description: Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
Study: NCT02332616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study: NCT04610827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Guideline-recommended 3 mg/kg/day dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Guideline-recommended 3 mg/kg/day dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Guideline-recommended 3 mg/kg/day dosing
Study: NCT00089505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200/300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200/300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200/300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200/300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400/100 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400/100 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally
Study: NCT02230644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced clinical environment
Description: Surgical booths containing artwork and calming background music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other distraction
Description: Such as newspaper, magazine or the news on television
Study: NCT00125268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIRE
Description: Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device is non-active but otherwise identical to the study device.
Study: NCT04169126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 PMPBB3
Description: The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Study: NCT04059354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech therapy addressing phonology and motor learning
Description: Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
Study: NCT02381795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Study: NCT00460499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A IV Insulin drip
Description: These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B Low Dose GIK
Description: These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C High Dose GIK
Description: This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
Study: NCT01709240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioWeld1 System
Description: External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
Study: NCT03797391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-01
Description: In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met.
Study: NCT01278316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
Study: NCT01565395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinum Toxin A
Description: Xeomin 70-100 units injected in the parotid and submandibular glands of subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sterile preservative free 0.9% saline
Study: NCT04036994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy
Description: All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
Study: NCT00693472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Preladenant, one 25 mg capsule, administered orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Preladenant, one 25 mg capsule, administered orally every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule administered orally every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anticholinergic agents or propanolol
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic agents or propanolol
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic agents or propanolol
Description: Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
Study: NCT05087407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting seton
Description: Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
Study: NCT04094207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
Study: NCT01244997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant
Description: This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant
Description: This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
Study: NCT00693472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day